TX-FLUENCE
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced its upcoming schedule of speakers who will present at virtual and in-person horticulture and cannabis industry conferences this fall.
“We’re thrilled our speakers are joining industry thought leaders from across the world to share their deep knowledge with cultivators, researchers, partners and others,” said David Cohen, CEO of Fluence. “At Fluence, our experts lead with science and are dedicated to advancing the industry’s awareness and application of LED lighting technologies to better understand the interaction between light and life. We look forward to connecting with conference participants, engaging in valuable conversations and discussing insights and learnings about what’s possible for LED lighting technology.”
Fluence’s roster of speakers includes:
- NCIA’s Midwest Cannabis Business Conference : Corinne Wilder, vice president of global operations, will speak with Dario Boyce from Anderson Porter Design and Jesse Porter from Inspire Transpiration Solutions on Sept. 23 at 12:00 p.m. CST about guidelines and policy for resource efficiency, including HVAC, lighting and control systems.
- NYC AgTech Week : Steve Graves, vice president of business development, will speak with Alina Zolotareva from AeroFarms, Tisha Livingston from Infinite Acres, Dr. Mary Ellis from Earle & Associates Ltd. and Penny McBride from FarmTech Society on Sept. 24 at 1:45 p.m. CST about trends in global controlled environment agriculture.
-
GreenTech Amsterdam
:
- Timo Bongartz, general manager of EMEA, will speak with Brad Nattrass from urban-gro and Nic Easley from 3C Consulting, LLC on Sept. 29 at 8:00 a.m. CST about market insights, challenges and opportunities for medical cannabis.
- Leo Lansbergen, horticulture service specialist, will speak with Max van den Hemel from Delphy Improvement Centre, Marc van Oers from Van Iperen International and Eri Hayashi from the Japan Plant Factory Association on Sept. 28 at 5:15 a.m. CST about crop management and optimization.
- Theo Tekstra, technical director, will speak with Lisanne Meulendijks from Delphy Improvement Centre, Andrew Jenkins from TU Delft and Aleksander Nastov from Samsung on Sept. 29 at 7:00 a.m. CST about vertical farming.
- HortiCann Light + Tech : Dr. Abhay Thosar, director of horticulture services, will speak with Adam Shinners from Superior Fresh on Sept. 29 at 3:00 p.m. CST about sustainability and best cultivation practices, efficiencies and optimized lighting strategies in commercial food production.
- Indoor Ag-Con : Steve Graves, vice president of business development, will participate in a panel on Oct. 4 at 9:30 a.m. CST about the next technical frontier for lighting.
- Benzinga Cannabis Capital Conference : David Cohen, CEO of Fluence, will give an exclusive on-stage interview during Benzinga’s hybrid event on Oct. 15 at 12:10 p.m. CST.
- MJBizCon : Corinne Wilder, vice president of global operations, will speak with David Hess from Tress Capital and Derek Smith from the Resource Innovation Institute on Oct. 22 at 12:30 p.m. CST about environmental and sustainability practices.
- 2021 Plant Lighting Short Course : Dr. David Hawley, principal scientist, will speak on Oct. 28 at 1:00 p.m. CST about lighting for indoor agriculture.
- Grow Up Conference & Expo : Taylor Kirk, horticulture service specialist, will join cannabis experts on Dec. 1 at 9:15 a.m. CST to discuss growers’ experiences and expectations with LED lighting in cannabis cultivation.
For information about Fluence’s upcoming speaking engagements, including more presentation details, how to register and how to contact the Fluence team at their upcoming conferences, visit www.fluence.science/events-main .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit www.fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210923005773/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom